1-20 of 20
Laurie H. Sehn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-Soo Yoon, Carlos Panizo, Ian Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4926–4935.
https://doi.org/10.1182/bloodadvances.2022009260
Published: 2023
Includes: Supplemental data
Journal Articles

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Clinical Trials & Observations
Peter W. M. Johnson, Sriram Balasubramanian, Brendan Hodkinson, S. Martin Shreeve, Steven Sun, Srimathi Srinivasan, Andrew J. Steele, Jessica Vermeulen, Laurie H. Sehn, Wyndham H. Wilson
Journal: Blood Advances
Blood Adv (2023) 7 (10): 2008–2017.
https://doi.org/10.1182/bloodadvances.2022009389
Published: 2023
Includes: Supplemental data
Journal Articles

The outcome of older adults with classic Hodgkin lymphoma in British Columbia

Phoebe T. M. Cheng, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Graham W. Slack, Randy D. Gascoyne, Pedro Farinha, Jeffrey W. Craig, Brian Skinnider, Don Wilson, David W. Scott, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5924–5932.
https://doi.org/10.1182/bloodadvances.2022008258
Published: 2022
Includes: Supplemental data
Journal Articles

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

G. Tjitske Los-de Vries, Wendy B. C. Stevens, Erik van Dijk, Carole Langois-Jacques, Andrew J. Clear, Phylicia Stathi, Margaretha G. M. Roemer, Matias Mendeville, Nathalie J. Hijmering, Birgitta Sander, Andreas Rosenwald, Maria Calaminici, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard, Gilles Salles, Heike Horn, Wolfram Klapper, Luc Xerri, Catherine Burton, Reuben M. Tooze, Alexandra G. Smith, Christian Buske, David W. Scott, Yasodha Natkunam, Ranjana Advani, Laurie H. Sehn, John Raemaekers, John Gribben, Eva Kimby, Marie José Kersten, Delphine Maucort-Boulch, Bauke Ylstra, Daphne de Jong
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5482–5493.
https://doi.org/10.1182/bloodadvances.2022008355
Published: 2022
Includes: Supplemental data
Journal Articles

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

Clinical Trials & Observations
Diego Villa, Eva Hoster, Olivier Hermine, Wolfram Klapper, Michal Szymczyk, André Bosly, Michael Unterhalt, Lisa M. Rimsza, Colleen A. Ramsower, Ciara L. Freeman, David W. Scott, Alina S. Gerrie, Kerry J. Savage, Laurie H. Sehn, Martin Dreyling
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5285–5294.
https://doi.org/10.1182/bloodadvances.2022007371
Published: 2022
Journal Articles

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA

Clinical Trials & Observations
Alex F. Herrera, Samuel Tracy, Brandon Croft, Stephen Opat, Jill Ray, Alex F. Lovejoy, Lisa Musick, Joseph N. Paulson, Laurie H. Sehn, Yanwen Jiang
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1651–1660.
https://doi.org/10.1182/bloodadvances.2021006415
Published: 2022
Includes: Supplemental data
Journal Articles

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Clinical Trials & Observations
Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar
Journal: Blood Advances
Blood Adv (2022) 6 (2): 533–543.
https://doi.org/10.1182/bloodadvances.2021005794
Published: 2022
Includes: Supplemental data
Journal Articles

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach

Clinical Trials & Observations
Phoebe T. M. Cheng, Diego Villa, R. Petter Tonseth, David W. Scott, Alina S. Gerrie, Ciara L. Freeman, Tom Pickles, Andrea C. Lo, Pedro Farinha, Jeffrey W. Craig, Graham W. Slack, Randy D. Gascoyne, François Bénard, Don Wilson, Brian Skinnider, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3647–3655.
https://doi.org/10.1182/bloodadvances.2021004375
Published: 2021
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data
Journal Articles

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Clinical Trials & Observations
Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1483–1489.
https://doi.org/10.1182/bloodadvances.2020002982
Published: 2021
Includes: Supplemental data
Journal Articles

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Clinical Trials & Observations
Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Sahin, Gila Sellam, Mikkel Z. Oestergaard, Umberto Vitolo, Marek Trněný
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1283–1290.
https://doi.org/10.1182/bloodadvances.2020002690
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

Clinical Trials & Observations
William A. Wood, Donna S. Neuberg, J. Colton Thompson, Martin S. Tallman, Mikkael A. Sekeres, Laurie H. Sehn, Kenneth C. Anderson, Aaron D. Goldberg, Nathan A. Pennell, Charlotte M. Niemeyer, Emily Tucker, Kathleen Hewitt, Robert M. Plovnick, Lisa K. Hicks
Journal: Blood Advances
Blood Adv (2020) 4 (23): 5966–5975.
https://doi.org/10.1182/bloodadvances.2020003170
Published: 2020
Includes: Supplemental data
Journal Articles

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Clinical Trials & Observations
Diego Villa, Laurie H. Sehn, Kerry J. Savage, Cynthia L. Toze, Kevin Song, Wendie D. den Brok, Ciara L. Freeman, David W. Scott, Alina S. Gerrie
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3486–3494.
https://doi.org/10.1182/bloodadvances.2020002068
Published: 2020
Includes: Supplemental data
Journal Articles

Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA

Clinical Trials & Observations
Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1589–1593.
https://doi.org/10.1182/bloodadvances.2019001261
Published: 2020
Includes: Supplemental data
Journal Articles

Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray

Clinical Trials & Observations
Diego Villa, King L. Tan, Christian Steidl, Susana Ben-Neriah, Muntadhar Al Moosawi, Tamara N. Shenkier, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage, David W. Scott, Randy D. Gascoyne, Graham W. Slack
Journal: Blood Advances
Blood Adv (2019) 3 (23): 3953–3961.
https://doi.org/10.1182/bloodadvances.2019000989
Published: 2019
Includes: Supplemental data
Journal Articles

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Clinical Trials & Observations
Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H. Sehn, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Jorne Biccler, Joseph M. Connors, David W. Scott, Maher K. Gandhi, Kerry J. Savage, Tarec El-Galaly, Diego Villa, Chan Yoon Cheah
Journal: Blood Advances
Blood Adv (2019) 3 (13): 2013–2021.
https://doi.org/10.1182/bloodadvances.2019000251
Published: 2019
Journal Articles

PD-L1 and tumor-associated macrophages in de novo DLBCL

Clinical Trials & Observations
Ronald McCord, Christopher R. Bolen, Hartmut Koeppen, Edward E. Kadel, III, Mikkel Z. Oestergaard, Tina Nielsen, Laurie H. Sehn, Jeffrey M. Venstrom
Journal: Blood Advances
Blood Adv (2019) 3 (4): 531–540.
https://doi.org/10.1182/bloodadvances.2018020602
Published: 2019
Includes: Supplemental data
Journal Articles

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology

Lauren C. Chong, Susana Ben-Neriah, Graham W. Slack, Ciara Freeman, Daisuke Ennishi, Anja Mottok, Brett Collinge, Pau Abrisqueta, Pedro Farinha, Merrill Boyle, Barbara Meissner, Robert Kridel, Alina S. Gerrie, Diego Villa, Kerry J. Savage, Laurie H. Sehn, Reiner Siebert, Ryan D. Morin, Randy D. Gascoyne, Marco A. Marra, Joseph M. Connors, Andrew J. Mungall, Christian Steidl, David W. Scott
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2755–2765.
https://doi.org/10.1182/bloodadvances.2018023572
Published: 2018
Includes: Supplemental data
Journal Articles

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL

Clinical Trials & Observations
Monika Pilichowska, Stefania Pittaluga, Judith A. Ferry, Jessica Hemminger, Hong Chang, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, Jeremy S. Abramson, Athena Kritharis, Francisco J. Hernandez-Ilizaliturri, Izidore S. Lossos, Oliver W. Press, Timothy S. Fenske, Jonathan W. Friedberg, Julie M. Vose, Kristie A. Blum, Deepa Jagadeesh, Bruce Woda, Gaurav K. Gupta, Randy D. Gascoyne, Elaine S. Jaffe, Andrew M. Evens
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2600–2609.
https://doi.org/10.1182/bloodadvances.2017009472
Published: 2017
Includes: Supplemental data